Across Europe, the "biological missile" technology of ADCs is being aggressively adapted for autoimmune diseases, chronic inflammation, fibrosis, and infectious diseases.

This comprehensive list merges home-grown biotechs, large pharmaceutical internal units, and leading research institutes currently developing non-oncology targeted conjugates.